AI assistant
Sunshine Biopharma Inc. — Director's Dealing 2012
Oct 5, 2012
35352_dirs_2012-10-05_e0de7e5c-b193-4b04-9f9b-fb06ca428dc6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Sunshine Biopharma, Inc (SBFM)
CIK: 0001402328
Period of Report: 2011-12-21
Reporting Person: Slilaty Steve N. (Director, Chief Executive Officer, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-12-21 | Common Stock | C | 17000000 | — | Acquired | 34109194 | Indirect |
| 2012-09-04 | Common Stock | J | 2591500 | $0.05 | Disposed | 31517694 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-12-21 | Series A Preferred Stock | $0 | C | 17000000 | Disposed | 2034-10-15 | Common Stock (17000000) | Indirect |
Footnotes
F1: The 2,591,500 shares subject hereto were transferred by Advanomics Corporation, a privately held Canadian research and development company. Dr. Steve N. Slilaty is the CEO and principal shareholder of Advanomics and as such controls the disposition of these shares. The subject shares were transferred to four Advanomics shareholders in exchange for their shares in Advanomics. An arbitrary price of $0.05 per share was assigned to these shares for tax purposes. Neither Dr. Slilaty, individually, or Advanomics received any cash compensation for the transfer of these shares.